Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.

Abstract: A communication circuit including a first coupler, a transmission-data change detector configured to detect a change in transmission data input to a transmitter, and a received-data change detector configured to detect a change in received data output from a receiver. In a standby state in which the received-data change detector and the transmission-data change detector do not detect changes in the received data and the transmission data, an input side of the receiver is connected to the first coupler and an output side of the receiver is disconnected from the first port in a receiving path; and an input side of the transmitter is connected to the first port and an output side of the transmitter is disconnected from the first coupler in a transmitting path.

Abstract: Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

Abstract: An image acquisition unit configured to acquire an image representing a three-dimensional shape of a surface of a human body, a spinal-column arrangement estimation-unit configured to estimate spinal-column arrangement of the human body using accumulated data, and an angle calculation unit configured to calculate at least one of a Cobb angle and a rotation angle from the estimated spinal-column arrangement are included.

Abstract: An optical communication system includes a first communication system to communicate first information from a controller to a truck and a second communication system to communicate second information. The first communication system includes a first light emitter to output the first information, a first optical fiber to transport the light output from the first light emitter while letting the light leak therefrom, and a first light receiver to receive the light leaking from the first optical fiber. The second communication system includes a second light emitter to output second information, a second optical fiber to transport the light output from the second light emitter and input to the second optical fiber at some point along the second optical fiber, and a second light receiver to receive the light transported over the second optical fiber.

Abstract: A subject of the present invention is to provide an anti AQP3 antibody specifically recognizing the extracellular domain of aquaporin 3 (AQP3), which is one type of a water channel protein. By selecting a monoclonal antibody which specifically binds to an oligopeptide included in loop C as one of the extracellular domains of AQP3, an anti AQP3 antibody that is desired in the present invention is provided. An anti AQP3 monoclonal antibody of the present invention can directly bind, from the outside of a cell, to AQP3 present in a cell membrane. Furthermore, as an anti AQP3 monoclonal antibody of the present invention can have an inhibitory activity, the function of permeating a low molecular weight molecule or the like, which is carried by AQP3, can be suppressed.

Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Abstract: An estimation method according to the disclosure for estimating a parameter related to skin function, the estimation method includes an image acquisition step for acquiring a skin image in which unevenness of a skin surface is captured; an extraction step for extracting a feature vector based on topological information on the skin image from the skin image acquired in the image acquisition step; an estimation step for estimating the parameter related to skin function based on the feature vector extracted in the extraction step, using an estimation model constructed based on past actual measurement data in which feature vectors are associated with the parameter related to skin function; and a presentation step for presenting the parameter related to skin function estimated in the estimation step.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: A position/force controller performs a first conversion for distributing control energy to at least one of velocity or position energy and force energy, in accordance with a function to be realized, based on velocity (or position) and force information, which correspond to information relating to a position based on an operation of an actuator, and information serving as reference of control. The position/force controller calculates at least one of a velocity or position control amount and a force control amount based on at least one of the energies obtained through the distribution. The position/force controller integrates the calculated control amounts, performs a second conversion, and determines input to the actuator. The position/force controller performs a process, corresponding to increasing or decreasing performed on at least one of the velocity or position energy and the force energy together or independently, with satisfaction of a condition set for the control energy.

Abstract: The present invention provides an antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria containing an intestinal bacterium as an active ingredient, or a pharmaceutical composition for treating, ameliorating, or preventing an infectious disease or an inflammatory disease.

Abstract: A marker may determine sensitivity to an anti-cancer agent early after the start of treatment with the anti-cancer agent. The anti-cancer agent may include oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker including one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO, and RIB5P.

Abstract: A treatment-instrument insertion aid (10) for aiding insertion of a treatment instrument into a body includes an inner tube (20) having flexibility into which the treatment instrument is insertable, and an outer tube (30) having flexibility into which the inner tube (20) is insertable. Both end portions (20B) of the inner tube (20) are formed of a hard material, and an intermediate portion (20A) between both the end portions (20B) is formed of a soft material.

Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising, as an active ingredient, a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT). Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof. [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R4, R3, and R4 is —OH or -OAc; R2 is a halogen atom, —OH, or -OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.

Abstract: According to one embodiment, an X-ray computed tomography apparatus includes a gantry body, a column, and fixing equipment. The gantry body includes a bore to form a field of view, and also includes an X-ray tube and an X-ray detector. The column supports the gantry body so that the gantry body is vertically movable with a central axis of the bore extending vertically to a floor face. The fixing equipment fixes a subject holder so that the subject holder is located on a passage of the bore and partially in the bore in a phase of attaching a subject to the subject holder.

Abstract: Provided are a method for determining prognosis of endometrial cancer, a method for determining endometrial cancer patient compatible to preservation therapy, and a method for determining risk of endometrial cancer. The methods comprise detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell, endometrial cancer cell or tissue containing the cell. Prognosis of endometrial cancer, compatibility to preservation therapy, or risk of endometrial cancer of a subject is determined on the basis of the detected DNA methylation level.

Abstract: An analysis method includes: acquiring data corresponding to a mass spectrum obtained by subjecting a sample containing a microorganism to mass spectrometry; and acquiring information on Group A Streptococcus of emm type 1, based on the presence or absence, or magnitude of a peak in a first range of m/z of 10930 or more to 10945 or less in the mass spectrum.

Abstract: In the present invention, the influence by flora of the skin on dermatitis is examined by analyzing Tmem79-knockout model mice, and a bacterium having a suppressive effect on dermatitis is identified, and the present invention relates to a pharmaceutical composition derived from such a bacterium, containing as active components one or more substances selected from: (a) a bacterial cell of an ampicillin-sensitive bacterium, or a constituent component of the bacterium; (b) a culture supernatant of an ampicillin-sensitive bacterium, or a purified product from the culture supernatant; (c) an extract of an ampicillin-sensitive bacterium; and (d) a metabolite of an ampicillin-sensitive bacterium.

Abstract: A method for producing a brain organoid is provided, including a step of culturing a neuroectoderm marker-positive cell aggregate in a medium containing an extracellular matrix with a concentration of more than 10% by volume.